2 min read Health Mizuho Upgrades Sarepta Therapeutics to Outperform with $26 Target Editorial 6 November, 2025 Mizuho Securities has upgraded its rating for Sarepta Therapeutics (NASDAQ: SRPT) from neutral to...Read More
